Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | PRKACA | P17612 | 1/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | FLT4 | P35916 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5131090 | 1.00 | CA2 (0.57) | CA2CA1MAOAMAOBPTGS2 | |
| SCHEMBL2917517 | 1.00 | CA2 (0.57) | CA2CA1MAOAMAOBPTGS2 | |
| SCHEMBL11103438 | 0.86 | CA2 (0.71) | CA2CA1ALDH1A1LMNAMEN1 | |
| SCHEMBL11103451 | 0.86 | CA2 (0.71) | CA2CA1ALDH1A1LMNAMEN1 | |
| SCHEMBL24590569 | 0.85 | MAOA (0.56) | MAOAMAOBPTGS2ALDH1A1MAPK1 | |
| SCHEMBL18457430 | 0.85 | MAOA (0.56) | MAOAMAOBPTGS2ALDH1A1MAPK1 | |
| SCHEMBL18416073 | 0.84 | MAOA (0.54) | MAOAMAOBPTGS2ALDH1A1MAPK1 | |
| SCHEMBL8803477 | 0.84 | MAOA (0.54) | CA1MAOAMAOBPTGS2ALDH1A1 | |
| SCHEMBL12320662 | 0.84 | MAOA (0.54) | CA1MAOAMAOBPTGS2ALDH1A1 | |
| SCHEMBL4664485 | 0.84 | MAOA (0.54) | CA1MAOAMAOBPTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4051269-A1 | D-AMPHETAMINE COMPOUNDS, COMPOSITIONS, AND PROCESSES FOR MAKING AND USING THE SAME | KemPharm, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021086426-A1 | D-AMPHETAMINE COMPOUNDS, COMPOSITIONS, AND PROCESSES FOR MAKING AND USING THE SAME | KEMPHARM, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20100240651-A1 | WATER-SOLUBLE THALIDOMIDE DERIVATIVES | ZHANG HESHENG | 2010-09-23 | — | — | US | disclosed |
| EP-1607394-B1 | WATER-SOLUBLE THALIDOMINE DERIVATIVES | TIAN JIN HEMAY BIO TECH CO LTD (CN) | 2010-09-01 | — | — | EP | disclosed |
| US-7741342-B2 | Water-soluble thalidomine derivatives | Zhang, Hesheng (CN) | 2010-06-22 | — | — | US | disclosed |
| US-20060094730-A1 | having increased bioavailability when administered orally or by injection; used for treating erythema, behcet's syndrome, crohn's disease, rheumatoid arthritis, abnormal myeloidosis syndrome and tumors | ZHANG, HESHENG (CN) | 2006-05-04 | — | — | US | disclosed |
| EP-1607394-A1 | WATER-SOLUBLE THALIDOMINE DERIVATIVES | Tian Jin Hemay Bio-Tech Co., Ltd. (DE) | 2005-12-21 | — | — | EP | disclosed |
| US-5756650-A | COMPOSITION COMPRISING POLYAMIC ACID, CURE ACCELERATOR SELECTED FROM GROUP CONSISTING OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AMINO ACID COMPOUND, AROMATIC COMPOUND HAVING TWO OR MORE HYDROXYL GROUPS | KABUSHIKI KAISHA TOSHIBA (JP) | 1998-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240651-A1 | WATER-SOLUBLE THALIDOMIDE DERIVATIVES | CCNH, CBR1, CBR3 | CA2 2630/4885CA1 2350/4885MAOA 4747/4885 |
| US-20060094730-A1 | having increased bioavailability when administered orally or by injection; used for treating erythema, behcet's syndrome, crohn's disease, rheumatoid arthritis, abnormal myeloidosis syndrome and tumors | FCGRT, MALT1, IL1R1 | CA2 4111/4885CA1 4241/4885MAOA 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.